NL-OMON36081已完成2 期
A Multi-Center, Randomized, Double-Blind, Multiple Ascending Dose, Placebo-Controlled, Parallel Group 2-Part Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamic of the HCV Nucleoside Inhibitor RO5428029 in Healthy Subjects (Part A), and in Chronic Hepatitis C Genotype 1 Infected Patients (Part B). - RO5428029 in Chronic Hepatitis C Genotype 1 Infected Patients
适应症
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 入组人数
- 50
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 至 99（—）
入选标准
- •- Healthy subjects (Part A) or patients with chronic hepatitis C infection (Part B), 18 to 60 years of age, inclusive
- •- Body mass index (BMI) between 18 and 32 kg/m2, inclusive, and a minimum weight of 45 kg
- •- Female subjects/patients must be surgically sterile or post-menopausal
- •- Male subjects/patients and their partners of childbearing potential must use 2 methods of contraception
- •- For HCV patients:
- •- Hepatitis C genotype 1 of >/= 6 months duration at screening
- •- HCV RNA quantifiable (Roche COBAS TaqMan HCV Test) at screening
- •- HCV treatment-naïve
- •- Liver biopsy or non-invasive procedure within the past 2 years showing absence of cirrhosis
排除标准
- •- Pregnant or lactating women, and male partners of women who are pregnant or lactating
- •- Women with reproductive potential
- •- Positive test for drugs of abuse
- •- History (within 3 months of screening) of alcohol consumption exceeding 2 standard drinks per day on average (1 standard drink = 10 grams or 1 unit of alcohol
- •- History or symptoms of any significant disease or disorder
- •- History of active malignancy within the last 5 years, except for localized or in situ carcinoma (e.g. basal or squamous cell carcinoma of the skin)
- •- Positive for hepatitis B or HIV infection, and/ or HCV for healthy volunteers (Part A)
- •- For HCV patients:
- •- Decompensated liver disease or impaired liver function as defined by any history of ascites, hepatic encephalopathy, hepatocellular carcinoma or bleeding esophageal varices, or prothrombin international normalized ratio (PTINR) >/= 2.0 at screening
- •- Evidence of cirrhosis and/or incomplete transition to cirrhosis
- •- Presence or history of non-hepatitis C liver disease
研究者
相似试验
进行中（未招募）
不适用
A multi-center study to assess the safety, tolerability and drug levels in the human body in healthy volunteers (part A) and patients with Chronic Hepatitis C Genotype 1 (part B)Chronic Hepatitis CMedDRA version: 14.1Level: LLTClassification code 10019752Term: Hepatitis C virus (HCV)System Organ Class: 10022891 - InvestigationsEUCTR2011-000640-24-PLF. Hoffmann-La Roche Ltd100
进行中（未招募）
不适用
A multi-center study to assess the safety, tolerability and drug levels in the human body in healthy volunteers (part A) and patients with Chronic Hepatitis C Genotype 1 (part B)Chronic Hepatitis CMedDRA version: 14.1Level: LLTClassification code 10019752Term: Hepatitis C virus (HCV)System Organ Class: 10022891 - InvestigationsEUCTR2011-000640-24-NLF. Hoffmann-La Roche Ltd100
进行中（未招募）
不适用
A Multicenter, Randomized, Double-Blind, Double-Dummy, Parallel group, Dose Response Study of subcutaneous AVE5026 with an Enoxaparin Calibrator Arm in the Prevention of Venous Thromboembolism in Patients Undergoing Elective Total Knee Replacement Surgery - TREKPatients undergoing elective total knee replacement surgery (risk of venous thromboembolic event)MedDRA version: 8.1Level: LLTClassification code 10049909EUCTR2005-006202-26-GRSanofi-Synthelabo Recherche800
进行中（未招募）
1 期
This is a Phase 3, randomized, multi-center study that will evaluate upadacitinib versus dupilumab in adults (18 – 75 years of age) with moderate to severe AD who are candidates for systemic therapy. The study is comprised of a 35-day Screening Period, a 24-week blinded treatment period, and a 12-week Follow-up period.moderate to severe Atopic DermatitisMedDRA version: 21.1Level: LLTClassification code 10003639Term: Atopic dermatitisSystem Organ Class: 100000004858EUCTR2018-002264-57-HUAbbVie Deutschland GmbH & Co. KG650
进行中（未招募）
1 期
Clinical trial investigating the efficacy and safety of investigational drug TEV-48125 developed to prevent cluster headacheEpisodic Cluster headache (ECH)EUCTR2016-003278-42-ESTeva Branded Pharmaceutical Products R&D, Inc.300